Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of Glp-1 agonists and Dpp-4 inhibitors on cardiovascular and pancreatic outcomes
As a Pharm.D graduate and medical writer, I enjoy exploring evidence-based topics that bridge pharmacology and patient education
At Eternity Health Partners, we ensure that your treatment is customized to your unique needs
Exp Clin Endocrinol Diabetes 123:95100 Dambrova M, Makrecka-Kuka M, Kuka J, Vilskersts R, Nordberg D, Attwood MM, Smesny S, Sen ZD, Guo AC, Oler E, Tian S, Zheng J, Wishart DS, Liepinsh E, Schioth HB (2022) Acylcarnitines: nomenclature, biomarkers, therapeutic potential, drug targets, and clinical trials
Debruyne F, Barkin J, van Erps P, Reis M, Tammela TLJ, Roehrborn C